At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 25 enrolled
Drug / intervention
sunitinib malatedrug
Likely dose
sunitinib malate 37.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Mechanistic Radiographic and Biologic Phase 2 Single Agent Study of Sunitinib Malate in Relapsed/Refractory Esophageal and Gastroesophageal Cancers
In Brief
A Phase 2 clinical trial evaluating sunitinib malate for Esophageal Cancer. Completed, enrolled 25 participants across 1 site.
Detailed Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib works in treating patients with relapsed or refractory esophageal or gastroesophageal junction cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Cancer
CountriesUnited States
CollaboratorsPfizer
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2008
Enrollment StartJun 2008
Primary CompletionSep 2013
Study CompletionDec 2013
TodayJul 2026
First PostedJun 20, 2008
Enrollment StartJun 30, 2008
Primary CompletionSep 17, 2013
Study CompletionDec 30, 2013
TodayJul 2, 2026
Enrollment to primary: 5.2 yearsPosted 18.0 years ago
Interventions
sunitinib malatedrug
Sunitinib 37.5 mg daily for a 4 week cycle